Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.

Bioorg Med Chem Lett, 2009/12/01;19(23):6524-8.

Ioannidis S[1], Lamb ML, Davies AM, Almeida L, Su M, Bebernitz G, Ye M, Bell K, Alimzhanov M, Zinda M

Affiliations

PMID: 19857966DOI: 10.1016/j.bmcl.2009.10.054

Impact factor: 2.94

Abstract
The design, synthesis and biological evaluation of a series of pyrazol-3-ylamino pyrazines as potent and selective JAK2 kinase inhibitors is reported, along with the pharmacokinetic and pharmacodynamic properties of lead compounds.
MeSH terms
More resources
EndNote: Download